To understand the role of HER3 plays in response to anti-HER2 antibody treatment in both low and high HER2 expression cancer cells, we constructed a monoclonal antibody named HER2Mab using the variable domain sequences of rhuMAB 2C4 and the antibody was expressed in HEK293 cells. This evidence concerns the gene ERBB3 and cancer.